Salicylate fails to prevent the inhibitory effect of 5,8,11,14-eicosatetraynoic acid on human platelet cyclo-oxygenase and lipoxygenase activities.
Sodium salicylate is inactive both on cyclo-oxygenase and lipoxygenase prepared from human platelets. It prevents the inhibition of cyclo-oxygenase induced by aspirin, but does not counteract the inhibitory effect of 5,8,11,14-eicosatetraynoic acid on both enzymes. It also fails to interfere with the inhibitory activity of nordihydroguaiaretic acid on lipoxygenase. These data indicate that, unlike eicosatetraynoic acid, non-steroidal anti-inflammatory drugs interact with a site on cyclo-oxygenase distinct from the catalytic site, although related to it. Such a supplementary binding site is lacking on lipoxygenase.
D015117:5,8,11,14-Eicosatetraynoic Acid / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects / Q000201:enzymology*; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology*; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D008084:Lipoxygenase / Q000097:blood*; D011451:Prostaglandin-Endoperoxide Synthases / Q000097:blood*; D012459:Salicylates / Q000494:pharmacology*; D020156:Salicylic Acid
D005231:Fatty Acids, Unsaturated; D012459:Salicylates; D015117:5,8,11,14-Eicosatetraynoic Acid; D008084:Lipoxygenase; D011451:Prostaglandin-Endoperoxide Synthases; D020156:Salicylic Acid; D001241:Aspirin; D007213:Indomethacin